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Abstract
In the last decade, great advances have been made in understanding the genetic basis for focal segmental glomerulosclerosis 
(FSGS). Animal models using specific gene disruption of the slit diaphragm and cytoskeleton of the foot process mirror 
the etiology of the human disease. Many animal models have been developed to understand the complex pathophysiology 
of FSGS. Therefore, we need to know the usefulness and exact methodology of creating animal models. Here, we review 
classic animal models and newly developed genetic animal models. Classic animal models of FSGS involve direct podocyte 
injury and indirect podocyte injury due to adaptive responses. However, the phenotype depends on the animal background. 
Renal ablation and direct podocyte toxin (PAN, adriamycin) models are leading animal models for FSGS, which have 
some limitations depending on mice background. A second group of animal models were developed using combinations 
of genetic mutation and toxin, such as NEP25, diphtheria toxin, and Thy1.1 models, which specifically injure podocytes. 
A third group of animal models involves genetic engineering techniques targeting podocyte expression molecules, such as 
podocin, CD2-associated protein, and TRPC6 channels. More detailed information about podocytopathy and FSGS can be 
expected in the coming decade. Different animal models should be used to study FSGS depending on the specific aim and 
sometimes should be used in combination.
Keywords Animal model · Focal segmental glomerulosclerosis · Podocyte
Seong Heon Kim and Jae Il Shin equally contributed on this 
manuscript.
 * Seong Heon Kim 
 pedksh@gmail.com
 * Jae Il Shin 
 shinji@yuhs.ac
 Anne Katrin Dettmar 
 a.dettmar@uke.de
 Andreas Kronbichler 
 Andreas.Kronbichler@i-med.ac.at
 Heon Yung Gee 
 HYGEE@YUHS.AC
 Moin Saleem 
 moinsaleem@hotmail.com
1 Department of Nephrology, Yonsei University Wonju 
College of Medicine, Wonju, Gangwon, Republic of Korea
2 Pediatric Nephrology, Department of Pediatrics, Medical 
University Center Hamburg-Eppendorf, Hamburg, Germany
3 Department of Internal Medicine IV (Nephrology 
and Hypertension), Universitätskliniken Innsbruck, 
Anichstraße 35, 6020 Innsbruck, Austria
4 Department of Pharmacology, Yonsei University College 
of Medicine, Seoul, Republic of Korea
5 Paediatric Renal Medicine, University of Bristol, Bristol, UK
6 Department of Pediatrics, Pusan National University 
Children’s Hospital, Yangsan, Republic of Korea
7 Research Institute for Convergence of Biomedical Science 
and Technology, Pusan National University Yangsan 
Hospital, Yangsan, Republic of Korea
8 Department of Pediatrics, Yonsei University College 
of Medicine, 50 Yonsei-Ro, Seodaemun-gu, Seoul 120-752, 
Republic of Korea
9 Children’s Renal Unit, Bristol Royal Hospital for Children, 
Bristol, UK
753Clinical and Experimental Nephrology (2018) 22:752–763 
1 3
Introduction: overview of animal models 
for focal segmental glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS), first described 
by Rich in 1957 [1], is currently recognized as one of the 
most common causes of primary glomerular diseases in 
adults and its incidence has recently been increasing [2]. 
FSGS causes asymptomatic proteinuria or nephrotic syn-
drome (NS) with or without any renal insufficiency. In adults 
undergoing renal biopsy for the evaluation of proteinuria, 
FSGS accounts for approx. 35% of all cases and up to 80% 
of cases in African–American patients. In general, FSGS is 
a progressive form of kidney disease, accounting for 2.3% 
of patients with end-stage renal disease (ESRD) [3], and 
severe proteinuria at the time of diagnosis has been associ-
ated with poor renal prognosis [4]. The term FSGS summa-
rizes a unique histological pattern of the glomerular disease, 
consisting of sclerotic/fibrotic lesion in light microscopy, 
which can be found in only some (focal) glomeruli and spe-
cial parts of the single glomerulus (segmental). There are 
different causes underlying the development of a FSGS pat-
tern, and primary (idiopathic) FSGS has to be distinguished 
from secondary FSGS caused by known trigger. Regardless 
of the disease forms, the podocyte stands in the center of 
the disease and seems to be an important target in FSGS [5]. 
The pathomechanisms behind the different forms of FSGS 
disease appears to be similar, resulting in the same histologi-
cal picture. Therefore, it is justified and absolutely necessary 
to study the pathophysiology of FSGS across various ani-
mal models. Despite the differences in disease characteris-
tic between humans and animals, animal models have been 
an essential component of medical research for centuries. 
One of the most important differences is that many animal 
models reflect secondary FSGS, whereas primary FSGS is 
much more common disease form in human [6]. However, 
the final result of the pathology remains the same between 
the two disease forms, justifying the use of animal models 
in understanding the underlying mechanisms behind FSGS.
Genetic engineering in mice has recently been devel-
oped to advance our knowledge of kidney disease, including 
FSGS. Historically, the development of major animal mod-
els for FSGS involves direct podocyte injury and indirect 
podocyte injury due to adaptive responses. In both para-
digms, recent evidence indicates that podocyte depletion is 
a major factor mediating proteinuria and glomerulosclerosis. 
Podocyte-specific toxin models support that podocyte loss 
is sufficient to cause FSGS in a dose-dependent manner. 
Knockout and transgenic models have provided proof of 
concept that mutations in specific podocyte proteins mediate 
genetic forms of FSGS [7]. In this review, we describe the 
classic animal models of FSGS and focus on new genetically 
engineered animal models.
Classic animal models for FSGS
Renal ablation model
One of the first animal models created to study glomerular 
disease was based on renal ablation in rats. The Brenner 
group demonstrated that alterations in glomerular blood 
flow caused by renal ablation result in structural lesions. 
They suggested that sustained single nephron hyperfiltra-
tion might result in maladaptive consequences by damaging 
remnant glomeruli [8, 9]. The 5/6 nephrectomy model is 
produced by removing one kidney and ablating 2/3 of the 
remaining kidney. Alterations in glomerular structure due to 
severe renal mass reduction had been detected at as early as 
2 weeks in this model. At the 7th week, more than 50% of 
glomeruli revealed FSGS lesions, and all animals died by 90 
days [10]. Most rats are susceptible to glomerulosclerosis, 
while C57BL/6 mice are highly resistant to the develop-
ment of glomerulosclerosis. 129/Sv and Swiss-Webster mice 
are among the few mouse strains susceptible to developing 
sclerosis [11]. A 4/6 renal mass reduction results in a milder 
variant of FSGS, without the induction of hypertension [12].
This model mimics secondary FSGS in human due to 
loss of functional kidney tissue (due to trauma, tumor sur-
gery, severe obesity, and very low birth weight infant), even 
though the loss of nephron mass is more acute and drastic in 
the animal model compared to the human disease (Table 1).
Induction of FSGS using podocyte‑toxic drugs
Induction of FSGS-causing agents, specifically toxic to 
podocytes, can be used to cause FSGS in animals. The sever-
ity of FSGS is usually dose dependent, and the development 
of glomerular disease is reliable and relatively easy to handle 
in these models. Such models are suitable for studying the 
effect of protective and curative treatments or for examining 
the precise pathomechanism of proteinuric nephropathies.
Puromycin aminonucleoside
Puromycin aminonucleoside (PAN) is an antibiotic that 
inhibits protein synthesis. PAN nephropathy can be induced 
in rats through various induction regimen, such multiple 
intraperitoneal injections or single intravenous administra-
tion with or without concomitant unilateral nephrectomy 
[13, 14]. Massive proteinuria develops within days of sin-
gle-dose administration of PAN (50 mg/kg body weight), 
and the kidney shows complete effacement of podocyte foot 
processes. The early phase of this model resembles mini-
mal change disease in human. A phase of almost complete 
remission is followed by steady, progressive, lower level pro-
teinuria, developing between weeks 10 and 13, associated 
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with early FSGS lesions. Follow-up of these animal models 
months after PAN administration shows glomerular sclerosis 
and progressive renal failure [15, 16]. By week 18, approxi-
mately 10–15% of the glomeruli show well-defined segmen-
tal sclerosis. The course is accelerated with uni-nephrectomy 
and multiple intraperitoneal injections (10 mg/kg body 
weight for the first dose, followed by additional doses of 
40 mg/kg body weight at every 4 week), with well-defined 
glomerulosclerosis developed by week 8 [17, 18] (Table 1).
Adriamycin model
Adriamycin is a well-known toxic agent of renal injury in 
rats, which mirrors histological changes that are observed in 
human chronic kidney disease (CKD) due to primary FSGS. 
Sternberg et al. were the first to publicate the use of anthra-
cyclines to cause renal injury [19]. This animal model of 
kidney disease has several benefits. It is a highly reproduc-
ible and a robust tissue injury model associated with little 
mortality (< 5%) and morbidity (weight loss) [20]. In male 
Wistar rats, the dose of adriamycin needed to induce renal 
injury ranges between 1.5 and 7.5 mg/kg. Male BALB/c 
mice require 9.8–10.4 mg/kg of the drug, while only 5.3 mg/
kg is required for male BALB/c SCID mice, an inbred lym-
phocyte-depleted strain of BALB/c mice. C57BL/c mice 
are highly resistant to adriamycin-induced renal injury, but 
renal injury may be inducible at higher doses (13–25 mg/
kg) than those required by BALB/c mice [21]. While most 
studies employ single injection regimen, regimens using 
multiple injections have also been reported [22–25]. After 
16 weeks, the FSGS phenotype is observed with progression 
to global glomerulosclerosis and tubulointerstitial fibrosis at 
24 weeks. Due to increased serum urea levels, some animals 
do not survive beyond 28 weeks [26].
Similar to Adriamycin, PAN model is directly toxic 
to podocytes and causes podocyte damage, elevates the 
endothelial permeability, and so reduces glomerular selec-
tivity, which secondarily leads to tubulointerstitial injury. 
The biggest disadvantage of these drug-induced models is 
the uncertainty of their similarity to human pathogenesis of 
FSGS [20] (Table 1).
Models with spontaneous FSGS
Buffalo/MWF model
Buffalo/Mna rats are a strain with a benign thymoma and the 
spontaneous development of proteinuria and nephrosclero-
sis [27]. The reason for the development of the FSGS-like 
lesions is not yet clear, but a circulating nephrotoxic factor 
in addition to aging and hypertension has been considered, 
because proteinuria had recurred after kidney transplantation 
from healthy Lewis rats. This suggested the involvement of 
a circulating proteinuric factor, which might correspond to 
relapsing idiopathic nephrotic syndrome in humans. Akiy-
ama et al. found that Arp3 is a candidate for the Pur1 gene, 
which has been identified in Buffalo/Mna rats through a 
quantitative trait locus (QTL) for proteinuria. Abnormal 
signaling-induced assembly of actin in podocytes leads to 
the development of FSGS [28]. The slower progression of 
the disease also mimics the slower development in human 
disease [29, 30]. Nevertheless, the slower pace of deterio-
ration also brings disadvantages for practical research use 
(Table 1).
Munich‑Wistar‑Fromter rat
Munich-Wistar-Fromter (MWF) rats are a strain character-
ized by a lower nephron count than standard Wistar rats [31]. 
Quantitative trait mapping and total genome scan reveals a 
locus on chromosome 6 associated with increased albumi-
nuria [32]. By the early age of 10 weeks, MWF rats develop 
proteinuria, and their systolic blood pressure (SBP) ranges 
from 140 to 150 mmHg. By 9 months of age, SBP reaches 
180 mmHg and the kidney exhibits significant glomerulo-
sclerosis. Notably, these phenomena are more prominent in 
males than in females despite similar nephron deficit. Higher 
single nephron glomerular filtration rates and glomerular 
volume in males than females may contribute to this gender 
difference [33] (Table 1).
NEP25 mouse model
The Nep25 mouse model is a model exclusively target-
ing the podocyte. A transgenic mouse strain (NEP25) that 
expresses human CD25 selectively in podocytes has been 
generated [34]. Injection of anti-Tac (Fv)-PE38 (LMB2), 
an immunotoxin with specific binding to human CD25, 
induces progressive nonselective proteinuria, ascites, and 
edema in NEP25 mice. Podocytes in these mice showed 
foot process effacement, vacuolar degeneration, detachment, 
and downregulation of synaptopodin, WT-1, nephrin, and 
podocalyxin. Mesangial cells developed matrix expansion, 
increased collagen, mesangiolysis, and, later, sclerosis. Pari-
etal epithelial cells showed vacuolar degeneration and pro-
liferation, whereas the endothelial cells were swollen. The 
severity of glomerular injury was LMB2 dose dependent. 
Using dosage of at least 1.25 ng/g body weight, NEP25 mice 
developed progressive glomerular damage and died within 2 
weeks. At dosage of 0.625 ng/g body weight, NEP25 mice 
survived for more than 4 weeks and developed focal seg-
mental glomerular sclerosis. Thus, this study established a 
mouse model of acquired progressive glomerular sclerosis in 
which onset and severity can be preprogrammed by specific 
maneuvers [35] (Table 1).
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Diphtheria toxin model
A transgenic rat strain in which the human diphtheria toxin 
(DT) receptor is specifically expressed in podocytes was 
developed. The rodent homologue does not act as a diph-
theria toxin receptor, thereby making rodents resistant to DT. 
Injection of DT (1 ml/10 g) into transgenic rats resulted in 
dose-dependent podocyte depletion from glomeruli. Three 
stages of glomerular injury caused by DT-induced podocyte 
depletion have been identified: Stage 1, 0–20% depletion 
with mesangial expansion, transient proteinuria, and normal 
renal function; stage 2, 21–40% depletion with mesangial 
expansion, capsular adhesions (synechiae), focal segmental 
glomerulosclerosis, mild persistent proteinuria, and nor-
mal renal function; and stage 3, > 40% podocyte depletion 
with segmental to global glomerulosclerosis with sustained 
high-grade proteinuria and reduced renal function [36]. This 
model also is very suitable for research purposes because of 
its predictability. In addition, it provides important informa-
tion regarding the development of secondary changes due 
to podocyte loss, but like many other models, it might not 
address the primary form of FSGS (Table 1).
HIV‑nephropathy model
HIV-associated nephropathy (HIVAN) is one of the lead-
ing causes of ESRD worldwide. Therefore, understanding 
this particular secondary form of FSGS and mechanisms 
associated with its aggravation and amelioration is impor-
tant. To do so, animal models for HIV-induced nephropathy 
are absolutely essential. There are different virus-induced 
animal models for FSGS research. Most of them are HIV-1-
based models. HIVAN transgenic mouse model was created 
using a replication-deficient version of HIV as the integrated 
transgene called transgenic 26 (Tg26). Proteinuria was first 
observed at 24 days of age. Around 20% of these mice died 
between 2 and 6 months with increased proteinuria, elevated 
blood urea nitrogen, edema, ascites, and hypoalbuminemia 
[37, 38]. Pathologically, the kidneys from uremic animals 
demonstrate collapsing lesions at a certain time point, dif-
fuse segmental and global glomerulosclerosis, and micro-
cystic tubular dilatation. These changes are remarkably simi-
lar to HIVAN [39, 40]. HIVAN probably develops because 
of the direct infection of podocytes and the local release of 
inflammatory cytokines. The HIV-1 transgenic mouse model 
demonstrated an immediate etiologic link between HIV-1 
inclusion into glomerular cells and the secondary develop-
ment of HIVAN with unique viral–host interactions. Both 
stimulating features of the virus and the individual nature of 
the host response contribute to this interaction. Infection of 
renal cells by HIV-1 was detected by RT-PCR of gag RNA 
at a low level. Some studies using HIV-1 transgenic mouse 
models have shown that the invasion of HIV-1 in kidneys 
is required for development of HIVAN. The final common 
pathway in the development of HIVAN most likely involves 
altered patterns of gene expression in renal parenchyma cells 
caused by cytokines and growth factors, leading to intersti-
tial fibrosis and enhanced glomerular matrix synthesis. The 
nature of the host response to viral infection is critical to the 
development of nephropathy [41] (Table 1).
Thy‑1.1 transgenic mouse model
The Thy-1.1 transgenic mouse is a podocyte-specific 
injury model, which should not be confused with the Thy-
1.1 rat model. Kollias et al. generated transgenic mice for 
a hybrid gene composed of the 5′ part of mouse Thy-1.1 
gene combined with 3′ human untranslated regions. Ectopic 
expression of the Thy-1.1 transgene induced spontaneous 
development of albuminuria within 8 weeks after birth and 
induced FSGS lesions in approximately 20% of glomeruli 
at 6 months of age [42]. In 2002, Assman et al. established 
an inducible model of FSGS in heterozygous animals by the 
injection of anti-Thy-1.1 monoclonal antibodies. Animals 
developed acute proteinuria caused by the damage of podo-
cytes and parietal cells in dose-dependent manner. It is an 
excellent inducible model to study the relationship between 
podocyte injury, albuminuria, and the development of FSGS 
[43, 44] (Table 1).
New genetically engineered mouse models 
for FSGS
Genetic engineering in animal models revealed the possi-
bility of studying functions of many novel genes and pro-
teins. However, so far, mutations can be identified only in a 
minority of patients with FSGS patients. Nevertheless, these 
animal models are essential in investigating functions of a 
single protein or protein–protein interactions as well as their 
consequences to determine the prognosis of the underlying 
disease. We focused on phenotypic FSGS models with podo-
cyte abnormalities and finally glomerulosclerosis excluding 
just only proteinuria.
Actin cytoskeleton
α‑Actinin 4 model
α-Actinin 4 is an actin-associated cross-linking protein. 
Patients with mutations in α-actinin 4 gene develop FSGS 
with an autosomal dominant inheritance pattern. The mutant 
protein leads to impaired dynamics of the actin cytoskeleton 
in podocytes and deterioration of podocyte slit diaphragm, 
resulting in early development of proteinuria and FSGS. 
Knock-in-mouse models have been generated to examine 
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the role of different human mutations [45, 46]. These studies 
helped to identify the purpose and physiological role of this 
cross-linking protein and the consequence and the severity 
of point mutations [47, 48] (Table 2; Fig. 1).
Myosin 1e model
Myosin 1e (Myo1e) is one of the two Src homology 
3 domain-containing “long-tailed” type I myosins in 
Table 2  Comparison of genetics between animal model and human model for FSGS
NS nephrotic syndrome, FSGS focal segmental glomerulosclerosis, M mouse, SD slit diaphragm, GBM glomerular basement membrane
Animal model Human model Affected location
α-Actinin-4 [46–48] α-Actinin-4 [45] Actin filament cross-linking protein/Interacts with integ-
rins and strengthens the podocyte-GBM interaction
Atypical protein kinase C [68–71] Tight junctions/Formation of Par complex and interacts 
with slit diaphragm
Rhophilin-1 [80] Rho GTPase activating protein 24 [80] Cytoplasm/Rho GTPase-interacting protein, integrity of 
glomerular filtration barrier
Angiotensin II receptor [55–57] Angiotensin-converting enzyme [55–57] Membrane/pseudocyst formation at podocyte
CD2-associated protein [65–67] CD2-associated protein [64] Insertion site of the slit diaphragm/Formation SD com-
plex with podocin and nephrin
Laminin subunit beta-2 [81–84] Laminin subunit beta-2 [81–84] Podocyte anchoring and differentiation in GBM
microRNA 193α [74, 75] Cytoplasm/Inhibition of expression of WT-1
Myosin 1e [49, 50] Myosin 1e [49, 50] Actin binding long-tailed motor protein/Regulation of 
actin cytoskeleton
Nuclear factor of activated T cells [76, 77] Transient receptor potential 6 [53, 54] Membrane/the activation of calcineurin-NFAT/Wnt sign-
aling via the increased calcium influx
Podocin [46] Podocin [58, 59] Insertion site of the SD/SD assembly and maintaining the 
signaling of nephrin
Shroom family member 3 [51, 52] Shroom family member 3 [51, 52] Actin filament development/glomerular sclerosis
Transcription factor 21(Pod1) [78] Cytoplasm/Development of endothelial and mesangial 
cell
Van Gogh-like protein 2 [72, 73] SD/Planar cell polarity signaling pathway for morpho-
genesis
Wilms tumor suppressor 1 [79] Downregulation of nephrin and synaptopodin
Fig. 1  Schematic diagram of genetically affected location for FSGS 
model. Myo 1e myosin 1e, TRCP6 transient receptor potential 6, 
AngII/AT1R angiotensin II/angiotensin receptor 1, Vangl protein Van 
Gogh-like protein, aPKC atypical protein kinase C, WT-1 Wilm’s 
tumor suppressor-1, NFAT nuclear factor of activated T cell, Tf21 
transcription factor 21, miRNA 193α microRNA 193α
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vertebrates. Myo1e-KO mice exhibited proteinuria, signs of 
chronic renal injury, and kidney inflammation. Renal tissue 
from Myo1e-null mice demonstrated histological character-
istic of glomerular disease at ultrastructural level, including 
a thickened and disorganized glomerular basement mem-
brane and flattened podocyte foot processes [49]. Myo1e 
in humans has an important role in podocyte function and 
the consequent integrity of glomerular permselectivity bar-
rier. The mutation leads to childhood onset steroid-resistant 
FSGS [50] (Table 2; Fig. 1).
Shroom 3
Shroom3 is an actin-associated protein that regulates epi-
thelial cell and tissue morphogenesis by binding F actin 
and regulating its subcellular organization. Shroom3 
interacts and recruits Rho-kinase (Rock), resulting in the 
phosphorylation and activation of nonmuscle myosin II 
(MyoII). Activation of this Rock/MyoII signaling pathway 
causes localized contraction of actin–myosin networks at 
the apical surface of the podocyte, resulting in changes in 
cell morphology [51]. In addition, Shroom3 heterozygous 
(Shroom3Gt/+) mice showed developmental abnormalities 
that manifested as adult-onset glomerulosclerosis and pro-
teinuria [52] (Table 2; Fig. 1).
Apical cell surface
Transient receptor potential channel 6 model
The latest advance in familial FSGS has been the discovery 
of a mutant form of canonical transient receptor potential 
cation channel 6 (TRPC6). This mutation leads to a gain 
of function and a transient increase of intracellular calcium 
concentration [53]. Krall et al. described the generation and 
phenotypic characterization of three different transgenic 
mice lines with podocyte-specific overexpression of the 
wild type or any of two mutant forms of Trpc6 (P111Q and 
E896K) previously related to FSGS. Subnephrotic-range 
albuminuria was detected in almost all transgenic lines, 
similar to human phenotype. Histologically, these transgenic 
mice developed patterns of kidney disease similar to human 
FSGS. Transgenic mice showed 2–3-folds greater glomeru-
lar lesions than non-transgenic mice [54] (Table 2; Fig. 1).
Angiotensin II type 1 receptor
A novel transgenic rat model with an overexpression of 
the human AngII type 1 receptor (hAT1) in podocytes was 
developed to study the consequences of increased AT1 
signaling on the structure and function of the glomerular 
filter. Structural changes at the glomerulus were encoun-
tered, starting with ubiquitous formation of pseudocysts at 
podocytes followed by foot process effacement and local 
detachments. This damage progressed to nephron loss via 
the well-known pathway typical for classic FSGS [55]. To 
evaluate angiotensin-converting enzyme (ACE) gene inser-
tion/deletion polymorphism in nephrotic syndrome, Lee 
et al. examined 85 patients (minimal change nephrotic syn-
drome [MCNS]: 55 cases, FSGS: 30 cases) and 61 controls. 
The distribution of ACE genotype in the control group was 
II 44%, ID 41%, and DD 15%. While the distribution of 
ACE genotypes in MCNS was similar to that in controls, the 
polymorphism pattern in FSGS was markedly different. The 
DD genotype was more frequent (p < 0.05) in FSGS than in 
MCNS. Patients with the DD genotype tended to present 
with earlier clinical symptoms. DD genotypes also showed 
lower responsiveness to corticosteroid therapy and a higher 
incidence of chronic renal failure. These results indicate that 
the ACE DD genotype in FSGS may be a risk factor for poor 
response to steroid therapy and the development of chronic 
renal failure [56]. However, the D allele or DD homozygo-
sity may become a significant genetic molecular marker for 
the onset of FSGS in Asians but not for Caucasians, Afri-
cans, Arabs, or Jews [57] (Table 2; Fig. 1).
Slit diaphragm
Nphs2 (podocin) model
Podocin is encoded by NPHS2 gene. It is a protein expressed 
at the site of slit diaphragm (SD) insertion in podocyte and 
is considered critical for SD assembly and nephrin signaling 
(46). Patients with mutations in the podocin gene develop 
familial and sporadic forms of FSGS. Since podocin-KO 
mice die within a few days of birth, the effect of its defi-
ciency on kidney function could not be investigated until 
recently [58]. Utilization of inducible Cre recombinase tech-
nology enabled the creation of a mouse model of podocin-
related NS through elective inactivation of podocin in 
mature mouse kidneys. Postnatal inactivation of podocin 
in mature kidneys by elective Cre induction led to massive 
proteinuria, glomerulosclerosis, and death in renal failure 
within a median of 11 weeks [59]. Nephrin (encoded by 
the NPHS1 gene) was identified as the cause of disease in 
congenital NS of the Finnish type [60]. Nephrin-KO mouse 
model confirmed the essential role of nephrin in SD struc-
ture and function [61, 62]. NPHS1-KO or inducible mice 
showed podocyte effacement with proteinuria and early post-
natal death, making it unsuitable for animal model of FSGS 
[63] (Table 2; Fig. 1).
CD2‑associated protein model
CD2-associated protein (CD2AP) is highly expressed in the 
glomerulus, binds to nephrin via its c-terminal domain, and 
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is localized to the SD [64]. Mice-lacking CD2AP had intact 
kidneys at birth, but foot process effacement developed after 
1 week. Proteinuria appeared at 2 weeks of age, and marked 
mesangial expansion occurred after 4 weeks. Few patients 
were identified with mutations for CD2AP [65]. Nonethe-
less, it still remains unclear how this mutation actually 
causes FSGS in humans [66]. Heterozygous CD2AP KO 
mice have been crossed with mice, heterozygous for muta-
tions in other podocyte genes such as Fyn or synaptopodin, 
also causing proteinuria and FSGS. Partial dysfunction of 
various podocyte proteins might synergistically predispose 
to NS [67] (Table 2; Fig. 1).
Atypical protein kinase C model
Atypical protein kinase C (aPKC), a component of the Par 
complex, localizes to tight junctions and interacts SD pro-
teins [68]. aPKC isoforms orchestrate formation of the podo-
cyte processes essential for normal glomerular development 
and kidney function. Defective aPKC signaling resulted in 
dramatically simplified glomerular architecture, leading to 
severe proteinuria and perinatal death [69, 70]. The regula-
tion of SD turnover by aPKC is crucial for maintenance of 
SD integrity, and defects in aPKC signaling can cause pro-
teinuria [71] (Table 2; Fig. 1).
Van Gogh‑like protein 2
The planar cell polarity (PCP) signaling pathway is crucial 
for tissue morphogenesis. Van Gogh-like protein 2 (Vangl2) 
is central in the PCP pathway. PCP signaling may be impor-
tant in kidneys for proper tubular morphogenesis and organi-
zation of glomerular epithelial cells along the glomerular 
basement membrane. Podocyte-specific deletion of Vangl2 
led to glomerular maturation defects in fetal kidneys. In adult 
mice, significantly smaller glomeruli were detected, but it 
did not affect glomerular permselectivity in aging animals. 
In the context of glomerular injury induced by injection of 
anti-glomerular basement membrane antibody, deletion of 
Vangl2 resulted in injury exacerbation and accelerated pro-
gression to chronic segmental and global glomerular scle-
rosis [72, 73] (Table 2; Fig. 1).
Nucleus
miRNA 193α (tg) model
miR-193a inhibits the expression of Wilms’ tumor protein 
(WT1), a transcription factor and master regulator of podo-
cyte differentiation and homeostasis. Decreased expression 
levels of WT1 lead downregulation of its target genes, spe-
cifically PODXL (podocalyxin) and NPHS1 (nephrin), as 
well as several other genes crucial for podocyte architecture, 
initiating a catastrophic collapse of the entire podocyte-
stabilizing system [74]. In mice, inhibition of miR-193a 
by complementary-locked nucleic acids resulted in the up-
regulation of the podocyte proteins synaptopodin and WT1. 
Conversely, the overexpression of miR-193a in isolated glo-
meruli resulted in vivo in up-regulation of parietal epithelial 
cell (PEC) markers and loss of podocyte markers. Inhibi-
tion of miR-193a in mouse model of nephrotoxic nephritis 
resulted in reduced crescent formation and decreased pro-
teinuria [75] (Table 2; Fig. 1).
Nuclear factor of activated T cells (NFAT), cytoplasmic 1 
model
Mutant forms of TRPC6 can activate nuclear factor of acti-
vated T-cell (NFAT)-dependent transcription in vitro via 
calcium influx and calcineurin activation. These TRPC6 
mutants can also cause FSGS, implying that NFAT acti-
vation may be a key intermediate step in the pathogenesis 
of mutant TRPC6-mediated FSGS. Wang et al. established 
a model of inducible NFAT activation, which revealed the 
influence of NFAT activation in TRPC6 mutations. Suppres-
sion of NFAT activity may contribute to the anti-proteinuric 
effects of calcineurin inhibitors [76, 77] (Table 2; Fig. 1).
Transcription factor 21 (Pod1) model
Tcf21 is a basic helix–loop–helix (bHLH) transcription 
factor which is highly expressed in developing and mature 
podocytes. Deletion of Tcf21 from podocytes and podo-
cyte progenitors using podocin-cre (podTcf21) and wnt4-
cre (wnt4creTcf21) driver strains, respectively, caused loss 
of Tcf21 from capillary-loop stage podocytes (podTcf21), 
resulting in simplified glomeruli with a decreased number 
of endothelial and mesangial cells. By 5 weeks of age, 40% 
of podTcf21 mice develop massive proteinuria and lesions 
similar to those of FSGS [78] (Table 2; Fig. 1).
Wilms tumor 1
Hall et al. reported a missense mutation of the transcrip-
tional regulator Wilms’ Tumor 1 (WT1) as the cause of 
non-syndromic, autosomal dominant FSGS in two Northern 
European kindreds from the United States. They performed 
sequential genome-wide linkage analysis and whole-exome 
sequencing to evaluate participants from family DUK6524. 
They identified a segregating missense mutation (R458Q) 
in WT1 isoform D as the cause of FSGS in this family. 
WT1 (R458Q) overexpression significantly downregulated 
nephrin and synaptopodin expression, promoted apopto-
sis in HEK293 cells, and impaired focal contact forma-
tion in podocytes. This mutation can alter the regulation of 
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podocyte homeostasis and causes non-syndromic FSGS [79] 
(Table 2; Fig. 1).
Basement membrane
Rhophilin‑1 model
Rhophilin-1 is a Rho GTPase-interacting protein, and its 
action on cytoskeleton organization is associated with inhib-
itory effects on Rho-dependent phosphorylation of the myo-
sin regulatory light chain and stress fiber formation. Con-
versely, phosphorylation of myosin regulatory light chain 
was increased in podocyte foot processes of Rhpn1(−/−) 
mice, implicating altered actinomyosin contractility in foot 
process effacement and compromised filtration capacity. 
Rhophilin-1 KO mice were phenotypically normal at birth, 
but developed albuminuria at about 2 weeks of age. Kidneys 
from severely albuminuric mice revealed widespread podo-
cyte foot process effacement, thickening of the glomerular 
basement membrane, and FSGS-like lesions. Rhophilin-1 is 
essential for the integrity of the glomerular filtration barrier 
and is a key determinant of podocyte cytoskeleton architec-
ture [80] (Table 2; Fig. 1).
Laminin beta2
Laminin beta2 is known to be abundantly expressed in 
the glomerular basement membrane and has a key role in 
anchoring as well as differentiation of podocyte foot pro-
cesses. Lamb2 knockout mice were reported to exhibit con-
genital nephrosis in association with anomalies of retina and 
neuromuscular junctions [81]. Pierson syndrome is a rare 
autosomal recessive disorder which is mainly characterized 
by congenital nephrotic syndrome (CNS), diffuse mesan-
gial sclerosis (DMS), and distinct ocular abnormalities, 
including microcoria. Most affected children exhibit early 
onset of chronic renal failure, neurodevelopmental deficits, 
and blindness. It is caused by a homozygous or compound 
heterozygous mutation in the gene encoding laminin beta2 
(LAMB2) on chromosome 3p21 [82, 83]. This mutation was 
proved in animal model which showed mesangial sclerosis 
and highly expressed LMB2 in basement membrane [84] 
(Table 2; Fig. 1).
Correlation with human FSGS subtype
The Columbia classification proposed in 2004 classified 
FSGS according to the morphology and intraglomerular 
location of sclerotic lesions. Five variants, namely, col-
lapsing, tip, cellular, perihilar, and not otherwise specified 
variants, were proposed [85]. Certain clinical situation is 
associated with specific variants. For example, collapsing 
variant, which is reported to result in the worst clinical 
outcome, is frequently associated with human immuno-
deficiency virus infection, while tip variant shows good 
response to treatment [86]. Although relatively little atten-
tion has been paid to morphologic subtypes of FSGS in 
animal models, some models were found to mimic certain 
variants of human FSGS. Collapsing variant has been most 
actively studied in terms of the pathogenesis of FSGS, 
focusing on the role of parietal epithelial cells [87]. In 
addition, perihilar variant was observed in renal ablation 
models, and tip variant was associated with intraglomeru-
lar shear reflecting the underlying pathogenetic mecha-
nisms of these variants [88].
The relationship between steroid‑resistant 
minimal change disease (MCD) and FSGS
We excluded animal models which showed only proteinuria 
or MCD features without glomerulosclerosis. In steroid-
resistant-type MCD, some genetic factors were proved by 
humanized mouse, which may be a good model that well 
reflects MCD pathophysiology to investigate suggested “T 
cell dysfunction” directly related to podocytes in vivo [89]. 
Several candidate circulating factors and their effects on 
podocytes have been proposed, but are still not sufficient 
to explain whole mechanisms and clinical features in MCD 
[90]. In FSGS, it is not clear if this is a distinct entity, or on 
the same spectrum, implicating the same circulating fac-
tors. These patients are mostly steroid resistant and often 
have a rapid relapse after transplantation [90]. The 45 genes 
currently associated with human NS explain not more than 
20–30% of hereditary and only 10–20% of sporadic cases 
[91]. Therefore, we need more detail explanation of patho-
mechanisms including genetic and immunologic combina-
tion studies for FSGS and steroid-resistant MCD.
Conclusion and future aspect
Although the pathomechanism of FSGS development is 
very complex, classic and new genetic models have allowed 
significant progress within the past several decades. Ani-
mal models of FSGS can now explain mechanisms involved 
in many secondary forms of chronic kidney disease with 
proteinuria. These models should provide a basis on which 
further progress of methodology in elucidating the patho-
physiology of podocytopathy can be made. Based on evi-
dences obtained from these animal models and observations 
in humans, the specific podocytopathy of kidney disease will 
be determined, allowing study of therapeutic options.
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